Cargando…

Targeting Ras-binding domain of ELMO1 by computational nanobody design

The control of cell movement through manipulation of cytoskeletal structure has therapeutic prospects notably in the development of novel anti-metastatic drugs. In this study, we determine the structure of Ras-binding domain (RBD) of ELMO1, a protein involved in cytoskeletal regulation, both alone a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tam, Chunlai, Kukimoto-Niino, Mutsuko, Miyata-Yabuki, Yukako, Tsuda, Kengo, Mishima-Tsumagari, Chiemi, Ihara, Kentaro, Inoue, Mio, Yonemochi, Mayumi, Hanada, Kazuharu, Matsumoto, Takehisa, Shirouzu, Mikako, Zhang, Kam Y. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023680/
https://www.ncbi.nlm.nih.gov/pubmed/36932164
http://dx.doi.org/10.1038/s42003-023-04657-w
Descripción
Sumario:The control of cell movement through manipulation of cytoskeletal structure has therapeutic prospects notably in the development of novel anti-metastatic drugs. In this study, we determine the structure of Ras-binding domain (RBD) of ELMO1, a protein involved in cytoskeletal regulation, both alone and in complex with the activator RhoG and verify its targetability through computational nanobody design. Using our dock-and-design approach optimized with native-like initial pose selection, we obtain Nb01, a detectable binder from scratch in the first-round design. An affinity maturation step guided by structure-activity relationship at the interface generates 23 Nb01 sequence variants and 17 of them show enhanced binding to ELMO1-RBD and are modeled to form major spatial overlaps with RhoG. The best binder, Nb29, inhibited ELMO1-RBD/RhoG interaction. Molecular dynamics simulation of the flexibility of CDR2 and CDR3 of Nb29 reveal the design of stabilizing mutations at the CDR-framework junctions potentially confers the affinity enhancement.